302 related articles for article (PubMed ID: 8376584)
1. beta 2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis.
Miyata T; Oda O; Inagi R; Iida Y; Araki N; Yamada N; Horiuchi S; Taniguchi N; Maeda K; Kinoshita T
J Clin Invest; 1993 Sep; 92(3):1243-52. PubMed ID: 8376584
[TBL] [Abstract][Full Text] [Related]
2. Involvement of beta 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-alpha and interleukin-1.
Miyata T; Inagi R; Iida Y; Sato M; Yamada N; Oda O; Maeda K; Seo H
J Clin Invest; 1994 Feb; 93(2):521-8. PubMed ID: 8113390
[TBL] [Abstract][Full Text] [Related]
3. Beta 2-microglobulin modified with advanced glycation end products induces interleukin-6 from human macrophages: role in the pathogenesis of hemodialysis-associated amyloidosis.
Iida Y; Miyata T; Inagi R; Sugiyama S; Maeda K
Biochem Biophys Res Commun; 1994 Jun; 201(3):1235-41. PubMed ID: 8024566
[TBL] [Abstract][Full Text] [Related]
4. New aspects in the pathogenesis of dialysis-related amyloidosis: pathophysiology of advanced glycation end products in renal failure.
Miyata T
Nihon Jinzo Gakkai Shi; 1996 May; 38(5):191-7. PubMed ID: 8699608
[TBL] [Abstract][Full Text] [Related]
5. Ultrastructural localization of advanced glycation end products and beta2-microglobulin in dialysis amyloidosis.
Brancaccio D; Gallieni M; Niwa T; Braidotti P; Coggi G
J Nephrol; 2000; 13(2):129-36. PubMed ID: 10858976
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous and lingual papules as a sign of beta 2 microglobulin-derived amyloidosis in a long-term hemodialysis patient.
Uenotsuchi T; Imafuku S; Nagata M; Kiryu H; Morita K; Koga T; Furue M
Eur J Dermatol; 2003; 13(4):393-5. PubMed ID: 12948922
[TBL] [Abstract][Full Text] [Related]
7. Advanced glycation end product-modified beta2-microglobulin is a component of amyloid fibrils of primary localized cutaneous nodular amyloidosis.
Fujimoto N; Yajima M; Ohnishi Y; Tajima S; Ishibashi A; Hata Y; Enomoto U; Konohana I; Wachi H; Seyama Y
J Invest Dermatol; 2002 Mar; 118(3):479-84. PubMed ID: 11874487
[TBL] [Abstract][Full Text] [Related]
8. Detection of novel beta 2-microglobulin in the serum of hemodialysis patients and its amyloidogenic predisposition.
Ogawa H; Saito A; Oda O; Nakajima M; Chung TG
Clin Nephrol; 1988 Sep; 30(3):158-63. PubMed ID: 3052955
[TBL] [Abstract][Full Text] [Related]
9. Amyloid beta 2-microglobulin is modified with imidazolone, a novel advanced glycation end product, in dialysis-related amyloidosis.
Niwa T; Katsuzaki T; Miyazaki S; Momoi T; Akiba T; Miyazaki T; Nokura K; Hayase F; Tatemichi N; Takei Y
Kidney Int; 1997 Jan; 51(1):187-94. PubMed ID: 8995733
[TBL] [Abstract][Full Text] [Related]
10. Monocyte/macrophage response to beta 2-microglobulin modified with advanced glycation end products.
Miyata T; Iida Y; Ueda Y; Shinzato T; Seo H; Monnier VM; Maeda K; Wada Y
Kidney Int; 1996 Feb; 49(2):538-50. PubMed ID: 8821842
[TBL] [Abstract][Full Text] [Related]
11. Haemodialysis-associated beta 2M amyloidosis: current controversies.
Stein G; Sperschneider H; Fünfstück R; Ritz E
Nephrol Dial Transplant; 1994; 9 Suppl 3():48-50. PubMed ID: 8072726
[TBL] [Abstract][Full Text] [Related]
12. Beta 2-microglobulin modified with advanced glycation end products modulates collagen synthesis by human fibroblasts.
Owen WF; Hou FF; Stuart RO; Kay J; Boyce J; Chertow GM; Schmidt AM
Kidney Int; 1998 May; 53(5):1365-73. PubMed ID: 9573554
[TBL] [Abstract][Full Text] [Related]
13. Modification of beta 2m with advanced glycation end products as observed in dialysis-related amyloidosis by 3-DG accumulating in uremic serum.
Niwa T; Katsuzaki T; Momoi T; Miyazaki T; Ogawa H; Saito A; Miyazaki S; Maeda K; Tatemichi N; Takei Y
Kidney Int; 1996 Mar; 49(3):861-7. PubMed ID: 8648931
[TBL] [Abstract][Full Text] [Related]
14. Identification of pentosidine as a native structure for advanced glycation end products in beta-2-microglobulin-containing amyloid fibrils in patients with dialysis-related amyloidosis.
Miyata T; Taneda S; Kawai R; Ueda Y; Horiuchi S; Hara M; Maeda K; Monnier VM
Proc Natl Acad Sci U S A; 1996 Mar; 93(6):2353-8. PubMed ID: 8637877
[TBL] [Abstract][Full Text] [Related]
15. Glycation of human beta 2-microglobulin in patients with hemodialysis-associated amyloidosis: identification of the glycated sites.
Miyata T; Inagi R; Wada Y; Ueda Y; Iida Y; Takahashi M; Taniguchi N; Maeda K
Biochemistry; 1994 Oct; 33(40):12215-21. PubMed ID: 7918443
[TBL] [Abstract][Full Text] [Related]
16. [Amyloid deposits in hemodialysis patients: immunochemical analysis].
Argiles A; Mourad G; Axelrud-Cavadore C; Cavadore JC; Mion C
Nephrologie; 1987; 8(2):51-4. PubMed ID: 3302740
[TBL] [Abstract][Full Text] [Related]
17. Beta 2 microglobulin isoforms in healthy individuals and in amyloid deposits.
Argilés A; García-García M; Derancourt J; Mourad G; Demaille JG
Kidney Int; 1995 Nov; 48(5):1397-405. PubMed ID: 8544395
[TBL] [Abstract][Full Text] [Related]
18. Advanced glycation end products stimulate tumor necrosis factor-alpha and interleukin-1 beta secretion by peritoneal macrophages in patients on continuous ambulatory peritoneal dialysis.
Rashid G; Korzets Z; Bernheim J
Isr Med Assoc J; 2006 Jan; 8(1):36-9. PubMed ID: 16450750
[TBL] [Abstract][Full Text] [Related]
19. Dialysis related amyloidosis: a disease of chronic retention and inflammation?
Floege J; Schäffer J; Koch KM; Shaldon S
Kidney Int Suppl; 1992 Oct; 38():S78-85. PubMed ID: 1405384
[TBL] [Abstract][Full Text] [Related]
20. Modification of beta 2-microglobulin with D-glucose or 3-deoxyglucosone inhibits A beta 2M amyloid fibril extension in vitro.
Hashimoto N; Naiki H; Gejyo F
Amyloid; 1999 Dec; 6(4):256-64. PubMed ID: 10611946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
